Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study

References

• Handorf EA, McElligott S, Vachani A, et al. Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. J Oncol Prac 2012;8:267-74
   PubMedGoogle Scholar
• Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer statistics review, 1975–2014. Bethesda, MD: National Cancer Institute. Available at: https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site
   Google Scholar
• National Cancer Institute (NIH). Financial burden of cancer care. NIH; 2017. Available at: https://progressreportcancergov/after/economic_burden
   Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN guidelines version 6.2107: non-small cell lung cancer. NCCN; 2017. Available at: https://nccn.org/
   Google Scholar
• Global Burden of Disease Cancer Center, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 2017;3:524-48
   PubMed Web of Science ®Google Scholar
• National Cancer Institute (NIH). Surveillance E, and End Results (SEER) program, SEER fast stats. NIH. Available at: https://seer.cancer.gov/faststats/
   Google Scholar
• Jakovljevic M, Malmose-Stapelfeldt C, Milovanovic O, et al. Disability, work absenteeism, sickness benefits, and cancer in selected European OECD countries—forecasts to 2020. Frontiers Public Health 2017;5:23
   PubMed Web of Science ®Google Scholar
• Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95:998-1004
   PubMed Web of Science ®Google Scholar
• Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol Offic J Am Soc Clin Oncol 2006;24:3340-6
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol Offic J Am Soc Clin Oncol 2013;31:3327-34
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:213-22
   PubMed Web of Science ®Google Scholar
• Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol Offic J Am Soc Clin Oncol 2013;31:3342-50
   PubMed Web of Science ®Google Scholar
• Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012;13:539-48
   PubMed Web of Science ®Google Scholar
• Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16:141-51
   PubMed Web of Science ®Google Scholar
• Morgillo F, Della Corte CM, Fasano M, et al. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO open 2016;1:e000060
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Spigel DR, Farley C, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007;110:2027-34
   PubMed Web of Science ®Google Scholar
• Langer CJ, O’Byrne KJ, Socinski MA, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol Offic Publ Int Assoc Study Lung Cancer 2008;3:623-30
   Google Scholar
• Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol Offic J Am Soc Clin Oncol 2010;28:911-17
   PubMed Web of Science ®Google Scholar
• Paramanathan A, Solomon B, Collins M, et al. Patients treated with platinum-doublet chemotherapy for advanced non-small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation. Clin Lung Cancer 2013;14:508-12
   PubMed Web of Science ®Google Scholar
• Fox KM, Brooks JM, Kim J. Metastatic non-small cell lung cancer: costs associated with disease progression. Am J Manag Care 2008;14:565-71
   PubMed Web of Science ®Google Scholar
• Dagovic A, Matter Walstra K, Gutzwiller SF, et al. Resource use and costs of newly diagnosed cancer initial medical care. Eur J Oncol 2014;19:166-84.
   Google Scholar
• HCUP Databases. Healthcare cost and utilization project (HCUP) agency for healthcare research and quality. Rockville, MD: HCUP; 2017. Available at: wwwhcup-usahrqgov/nisoverviewjsp
   Google Scholar
• CPI-U. US city average; physicians’ services; not seasonally adjusted. CPI-U. Available at: http://www.economagic.com/em-cgi/data.exe/blscu/CUSR0000SEMC01
   Google Scholar
• CPI-All Urban Consumers. Prescription drugs in U.S. city average, all urban consumers; seasonally adjusted. CPI. Available at: https://data.bls.gov/timeseries/CUSR0000SEMF01?output_view=pct_3mths
   Google Scholar
• CPI-U. US city average; inpatient hospital services; not seasonally adjusted. CPI-U. Available at: http://www.economagic.com/em-cgi/data.exe/blscu/CUUR0000SS5702
   Google Scholar
• Fernandes A, Skinner KE, Walker MS, et al. Understanding real-world outcomes in patients with NSCLC who progress on 1st-/2nd-generation EGFR TKIs. J Clin Oncol Offic J Am Soc Clin Oncol 2017;35(suppl; abstr e20589)
   Google Scholar
• G. B. D. 2015 Eastern Mediterranean Region Cancer Collaborators, Fitzmaurice C. Burden of cancer in the Eastern Mediterranean Region, 2005–2015: findings from the Global Burden of Disease 2015 Study. Int J Public Health. 2017. Epub 2017/08/05
   Google Scholar